Who is sponsoring NCT01992198?

NCT01992198 is sponsored by Erzhen Chen.

What drugs are being tested in NCT01992198?

Interventions in NCT01992198: cefoperazone + metronidazole, oral care by chlorhexidine gluconate, enteral nutrition, Somatostatin, Meropenem.

What condition does NCT01992198 study?

NCT01992198 studies Pancreatitis,Acute Necrotizing.

Is NCT01992198 still recruiting?

NCT01992198 is currently status unknown. Last updated 18 November 2013.

Last reviewed 2013-11-18 · How we verify

NCT01992198

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Escalade or Deseacalade Antibiotic Use in Severe Acute Pancreatitis

Status unknown Phase 4 Last updated 18 November 2013

What this trial tests

Phase 4 trial testing cefoperazone + metronidazole in Pancreatitis,Acute Necrotizing in 60 participants. Status unknown.

Timeline

1 July 2012

Primary endpoint
1 December 2015

1 December 2016

Quick facts

Lead sponsor	Erzhen Chen
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 July 2012
Primary completion	1 December 2015
Estimated completion	1 December 2016
Sites	1 location across China

Drugs / interventions tested

cefoperazone + metronidazole — full drug profile →
oral care by chlorhexidine gluconate
enteral nutrition — full drug profile →
Somatostatin (SOMATOSTATIN) — full drug profile →
Meropenem (Meropenem) — full drug profile →

Conditions studied

Pancreatitis,Acute Necrotizing — all drugs for Pancreatitis,Acute Necrotizing →

Sponsor

Erzhen Chen — full company profile →

Who can join

Adults 18 to 80, any sex, with Pancreatitis,Acute Necrotizing. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

pancreatic or peripancreatic infection
Time frame: 28-day

Sponsor's own description

Strategy of antibiotic therapy in SAP,De-escalate (cefoperazone+metronidazole) or Escalate (meropenem) therapy,which one is better.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cardiac indicator CK-MB might be a predictive marker for severity and organ failure development of acute pancreatitis.
Zhao B, Sun S, Wang Y, Zhu H, et al · · 2021 · cited 15× · PMID 33842589 · DOI 10.21037/atm-20-3095

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01992198 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Erzhen Chen
Last refreshed: 18 November 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01992198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing